At a glance
ClinicalIndex Comparison RecordN/ACompleted· 691 enrolled
Drug / intervention
Pregabalindrug
Likely dose
Pregabalin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessing the Treatment of Patients With Neuropathic Pain Using LYRICA; A Non Interventional Post-marketing Study (NI-PMS)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Feb 13, 2009·Updated Feb 10, 2021
In Brief
An observational study evaluating Pregabalin for Neuropathic Pain. Completed, enrolled 691 participants.
Detailed Summary
A Non-Interventional, Post-Marketing Surveillance (NI-PMS) study whose objectives were to assess the impact of pregabalin on subjects' pain, quality of sleep, and their general wellbeing, as well as the tolerance and safety of pregabalin in subjects with neuropathic pain.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
Primary CompletionMar 2008
First PostedFeb 2009
TodayJul 2026
First PostedFeb 13, 2009
Enrollment StartSep 1, 2006
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.4 years ago
Interventions
Pregabalindrug
Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks